Amgen ’s long-term analysis of Kyprolis’ ENDEAVOR trial shows favourable data

Amgen has reported positive data from a long-term analysis of the Phase III ENDEAVOR trial of Kyprolis (carfilzomib) for the treatment of relapsed or refractory multiple myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news